JP4018142B2 - 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法 - Google Patents

造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法 Download PDF

Info

Publication number
JP4018142B2
JP4018142B2 JP52692197A JP52692197A JP4018142B2 JP 4018142 B2 JP4018142 B2 JP 4018142B2 JP 52692197 A JP52692197 A JP 52692197A JP 52692197 A JP52692197 A JP 52692197A JP 4018142 B2 JP4018142 B2 JP 4018142B2
Authority
JP
Japan
Prior art keywords
cells
leptin
hematopoietic
cell
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52692197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510982A (ja
JP2001510982A5 (enExample
Inventor
スノッドグラス，エイチ．，ラルフ
シオフィー，ジョセフ
ズパンシック，トーマス，ジェイ．
シェファー，アラン，ダブル．
ミックヘイル，アベル，エー．
バラット，ブルース，エー．
Original Assignee
インデバス ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/618,957 external-priority patent/US6355237B1/en
Application filed by インデバス ファーマシューティカルズ，インコーポレーテッド filed Critical インデバス ファーマシューティカルズ，インコーポレーテッド
Publication of JP2001510982A publication Critical patent/JP2001510982A/ja
Publication of JP2001510982A5 publication Critical patent/JP2001510982A5/ja
Application granted granted Critical
Publication of JP4018142B2 publication Critical patent/JP4018142B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/355—Leptin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
JP52692197A 1996-01-23 1997-01-21 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法 Expired - Fee Related JP4018142B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US58991596A 1996-01-23 1996-01-23
US08/589,915 1996-01-23
US08/618,957 US6355237B1 (en) 1994-09-14 1996-03-20 Methods for using the obese gene and its gene product to stimulate hematopoietic development
US08/618,957 1996-03-20
US71329696A 1996-09-13 1996-09-13
US08/713,296 1996-09-13
PCT/US1997/000767 WO1997027286A1 (en) 1996-01-23 1997-01-21 Methods for using the obese gene and its gene product to stimulate hematopoietic development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006355150A Division JP2007163502A (ja) 1996-01-23 2006-12-28 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法

Publications (3)

Publication Number Publication Date
JP2001510982A JP2001510982A (ja) 2001-08-07
JP2001510982A5 JP2001510982A5 (enExample) 2004-11-11
JP4018142B2 true JP4018142B2 (ja) 2007-12-05

Family

ID=27416556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52692197A Expired - Fee Related JP4018142B2 (ja) 1996-01-23 1997-01-21 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法
JP2006355150A Pending JP2007163502A (ja) 1996-01-23 2006-12-28 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006355150A Pending JP2007163502A (ja) 1996-01-23 2006-12-28 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法

Country Status (10)

Country Link
EP (2) EP0892849B1 (enExample)
JP (2) JP4018142B2 (enExample)
AT (1) ATE320479T1 (enExample)
AU (1) AU731685C (enExample)
CA (1) CA2244693A1 (enExample)
DE (1) DE69735477T2 (enExample)
DK (1) DK0892849T3 (enExample)
ES (1) ES2260784T3 (enExample)
PT (1) PT892849E (enExample)
WO (1) WO1997027286A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ATE303437T1 (de) * 1996-01-04 2005-09-15 Amgen Inc Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
FR2767136B1 (fr) * 1997-08-06 2004-08-27 Genset Sa Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
WO2000012683A2 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
EP1127120B1 (en) 1998-11-04 2008-05-28 Serono Genetics Institute S.A. Genomic and complete cdna sequences of human adipocyte-specific apm1 and biallelic markers thereof
ES2323445T3 (es) 1999-02-10 2009-07-16 Serono Genetics Institute S.A. Marcadores polimorficos del gen lsr.
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR102563568B1 (ko) 2016-11-08 2023-08-04 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체에 길항하는 항원-결합 단백질
CA3084385A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor

Also Published As

Publication number Publication date
DE69735477D1 (de) 2006-05-11
EP1731164A1 (en) 2006-12-13
AU731685B2 (en) 2001-04-05
DK0892849T3 (da) 2006-07-24
ES2260784T3 (es) 2006-11-01
EP0892849A1 (en) 1999-01-27
AU1831197A (en) 1997-08-20
JP2001510982A (ja) 2001-08-07
CA2244693A1 (en) 1997-07-31
EP0892849A4 (en) 2004-08-25
ATE320479T1 (de) 2006-04-15
PT892849E (pt) 2006-08-31
WO1997027286A1 (en) 1997-07-31
DE69735477T2 (de) 2006-11-30
AU731685C (en) 2002-08-22
EP0892849B1 (en) 2006-03-15
JP2007163502A (ja) 2007-06-28

Similar Documents

Publication Publication Date Title
JP4018142B2 (ja) 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法
WO1997027286A9 (en) Methods for using the obese gene and its gene product to stimulate hematopoietic development
Paul et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.
EP0730606B1 (en) Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR
US7374934B2 (en) Cell populations and methods of production thereof
KR100319359B1 (ko) flt3수용체에대한리간드
Battista et al. Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation
JP3750819B2 (ja) Ｃ−ｋｉｔ受容体に対するリガンド及びその使用法
US5763211A (en) Isolated nucleic acid encoding Hu-B1.219, a novel human hematopoietin
US6838079B2 (en) Methods for using the obese product to stimulate hematopoietic development
Testa et al. Differential Expression Of IL-3 and GM-CSF Receptor Common Signal Transducing Subunit (βC) During Normal Hematopoietic Differentiation
SIGNAL TRANSDUCING SUBUNIT (ẞC) DURING
Frasca et al. Activation of gp130 signaling in vivo by the IL‐6 super‐agonist K‐7/D‐6 accelerates repopulation of lymphoid organs after irradiation
WO1999015560A1 (en) Soluble polypeptide having a delta-serrate-lag2 domain of delta homologue and uses thereof
Lin Studies of the role of transcription factor GATA-1 and the erythropoietin receptor in hematopoiesis
Morris Separation of the Mitogenic and Synergistic Activities of Interleukin-3
Krosl The role of erythropoietin and erythropoietin receptor in regulation of hemopoiesis
Cohen-Solal et al. Mpl-Ligand and the Regulation of Megakaryocytopoiesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040120

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070920

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100928

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees